FIG 6.
No protective efficacy against SIV rectal infection by any of the prime-boost regimens. At week 64 following a suboptimal boost with 1 × 107 PFU NYVAC-SIVgag-pol, 29 monkeys (for BCG Wt, n = 4; for the other groups, n = 5) were challenged weekly by the intrarectal route until viremia was detectable. (A) Viremia was detected in all monkey groups after a median of either 1 or 2 challenges (range, 1 to 7 challenges). (B) Peak viral loads were similar in all groups, regardless of prechallenge SIV Gag-specific immune responses. (C) Set point viral loads, measured at week 12 following viral acquisition, demonstrated more variation between groups than peak viral loads but lacked any indication of protection by the vaccines. For BCG Wt, n = 4; for the other groups, n = 5. Bars indicate medians.